Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event
September 30, 2024, Wuhan – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, successfully hosted the “Fuel BioGrowth Chime Day” event on September 27 at the East Lake Hotel in Wuhan. The event gathered top key opinion leaders (KOLs) and prominent investors from the global biopharmaceutical sector to explore cutting-edge innovations and discuss business growth opportunities in the rapidly evolving biologics industry.
The event was hosted by Peter Pang, General Manager of Chime Biologics Shanghai Innovation Center and Senior Vice President of Project Management Office & Regulatory Affairs. Jimmy Wei, President of Chime Biologics, delivered the opening speech,highlighting the leading role of China’s biopharmaceutical industry in driving global innovation.Wei highlighted the significance of a localization strategy to boost market presence and success,while also discussing the key focus of Chime as the gateway to globalization strategy.
Focusing on ADC and Biosimilars
Minmin Qin, founder of DD Technologies, presented the latest innovations in antibody-drug conjugate (ADC) technology, offering an in-depth analysis of the challenges faced in CMC process. Qin also shared effective strategies to overcome these hurdles, providing valuable insights into this rapidly evolving field.
Sarfaraz Niazi, Professor of Pharmaceutical Sciences at the University of Illinois Chicago, delivered a keynote speech on the new era of biosimilars. He shared the latest developments and future prospects for biosimilars,emphasizing their potential in improving drug accessibility and reducing costs. He also highlighted the regulatory and research challenges that must be addressed to fully realize the promise of biosimilars., while also pointing out the challenges faced in the research and regulatory approval process.
Decoding Biopharmaceutical Business Strategies
Moderated by Jimmy Wei,the first roundtable discussion focused on biopharmaceutical business strategies. The panelists included Konstantin Matentzoglu, Delegated Supervisory Board Member of Polpharma Biologics, Alan Harris, Senior Vice President of R&D at Ferring Pharmaceuticals,Wieland Wolf, Biopharmaceutical Consultant, and Nathan Chen, CEO of Hope Medicine. The discussion revolved the strategies global biopharmaceutical companies are using to adapt to a dynamic business environment, leveraging innovation and strategic alliances to fuel growth. Additionally, they explored the key factors in identifying optimal partners and the rationale behind such selections.The panelists’ insightful perspectives sparked engaging dialogue and earned rounds of applause from the audience.
Shaping the Future of Biopharmaceutical Innovation
The second roundtable discussion was moderated by Thomas Risko, Vice President of Manufacturing at Chime Biologics, highlighted the latest technological advancements that are reshaping the industry. The panelists included Ralf Gengenbach, General Manager & Owner of Gempex GmbH, Pengfei Zhou, Chairman & CEO of YZY Bio, Minmin Qin, founder of DD Technologies, and Zack Zheng, Chief Technology Officer & Senior Vice President of R&D at Chime Biologics.
The event concluded with a strong sense of the optimism about the future of the biopharmaceutical innovation, with participants leaving with a deeper understanding of the global market and the potential for future partnerships. Chime Biologics reaffirmed its commitment to fostering global industry growth and advancing the integration of biotechnology and ecological sustainability.
About Chime Biologics
Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information,please visit: www.chimebiologics.com .
